{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:29:58Z","timestamp":1786364998016,"version":"build-2736575974"},"reference-count":38,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100018556","name":"Suzhou Science and Technology Program","doi-asserted-by":"publisher","award":["SKJY2021004"],"award-info":[{"award-number":["SKJY2021004"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Suzhou Science and Technology Program","doi-asserted-by":"publisher","award":["SYWD2025094"],"award-info":[{"award-number":["SYWD2025094"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Suzhou Science and Technology Program","doi-asserted-by":"publisher","award":["MSXM2025058"],"award-info":[{"award-number":["MSXM2025058"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Medicine Science and Technology Development Fund of Jiangsu University","award":["JLY2021121"],"award-info":[{"award-number":["JLY2021121"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dose-Response"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy and safety of sintilimab combined with anlotinib and chemoradiotherapy as first-line treatment for driver gene-negative oligometastatic non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included patients with driver gene-negative oligometastatic NSCLC (single organ, \u22642 lesions) treated at the Affiliated Zhangjiagang Hospital of Soochow University (7\/2021\u201312\/2023). All patients received 4 cycles of sintilimab plus albumin-bound paclitaxel\/carboplatin and achieved partial response or stable disease. Subsequently, patients received concurrent radical radiotherapy with or without anlotinib, or continued the original regimen. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 88 patients were included: 27 in the sintilimab plus chemotherapy (SC) group, 32 in the sintilimab plus chemoradiotherapy (SCR) group, and 29 in the anlotinib plus sintilimab and chemoradiotherapy (ASCR) group. The radiotherapy group (SCR + ASCR) showed significantly longer median PFS and OS than the non-radiotherapy group (SC) (7.7 vs. 16.5 months, P &lt; 0.001; 20.1 vs. 31.8 months, P = 0.004). The ASCR group had significantly higher 12-month PFS, 18-month OS, and 24-month OS rates than the SCR group (P = 0.005, 0.014, and 0.046, respectively). ORR and DCR were significantly lower in the non-radiotherapy group (P &lt; 0.001 and P = 0.007). Treatment-related adverse events were manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In driver gene-negative oligometastatic NSCLC patients benefiting from first-line sintilimab plus chemotherapy, adding concurrent radical radiotherapy significantly improved survival with acceptable toxicity. The addition of anlotinib further enhanced long-term outcomes. These findings are preliminary and require prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15593258261476788","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:34:12Z","timestamp":1786145652000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Sintilimab in Combination With Anlotinib and Chemoradiotherapy as First-Line Treatment for Driver Gene-Negative Oligometastatic Non-small Cell Lung Cancer: A Real-World Cohort Study"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1098-2437","authenticated-orcid":false,"given":"Jian","family":"Jiang","sequence":"first","affiliation":[{"name":"Zhangjiagang Hospital Affiliated to Soochow University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ni","sequence":"additional","affiliation":[{"name":"Zhangjiagang Hospital Affiliated to Soochow University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Zhangjiagang Hospital Affiliated to Soochow University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Song","sequence":"additional","affiliation":[{"name":"Zhangjiagang Hospital Affiliated to Soochow University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9418-1675","authenticated-orcid":false,"given":"Huiping","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zhangjiagang Hospital Affiliated to Soochow University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00798-3"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030320"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.12.023"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.07.025"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.04.004"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30532-0"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06485-4"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0838"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03964-9"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_6_16_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"Institute NC","unstructured":"Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 24 January 2026."},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-C"},{"issue":"22","key":"e_1_3_6_18_2","first-page":"8105","article-title":"Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization","volume":"61","author":"Kotera Y","year":"2001","unstructured":"Kotera Y, Shimizu K, Mul\u00e9 JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61(22):8105-8109.","journal-title":"Cancer Res"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69219"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.12.025"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1478"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1449"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.9702"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.098"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8506"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.07.035"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14542-w"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112882"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-024-02489-4"},{"issue":"11","key":"e_1_3_6_33_2","first-page":"1135","article-title":"Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer (ORIENT-11): a randomised, double-blind, phase 3 trial","volume":"8","author":"Yang YWZ","year":"2020","unstructured":"Yang YWZ, Fang J, et al. Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer (ORIENT-11): a randomised, double-blind, phase 3 trial. Lancet Respiratory Medicine. 2020;8(11):1135-1145.","journal-title":"Lancet Respiratory Medicine"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.011"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12385"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12654"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2241"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12518"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-014-9420-y"}],"container-title":["Dose-Response"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15593258261476788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15593258261476788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15593258261476788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:47:45Z","timestamp":1786362465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15593258261476788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/15593258261476788"],"URL":"https:\/\/doi.org\/10.1177\/15593258261476788","relation":{},"ISSN":["1559-3258","1559-3258"],"issn-type":[{"value":"1559-3258","type":"print"},{"value":"1559-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"15593258261476788"}}